ArticleiScience2023
Preclinical evaluation of a COVID-19 vaccine candidate based on a recombinant RBD fusion heterodimer of SARS-CoV-2.
Open access · goldAbstract read
In one paragraph
Article in iScience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study.Human vaccines & immunotherapeutics · 2025Trial
- Comparative analysis of adenovirus, mRNA, and protein vaccines reveals context-dependent immunogenicity and efficacy.JCI insight · 2025Article
- Molecular mechanisms of SARS-CoV-2 entry: implications for biomedical strategies.Microbiology and molecular biology reviews : MMBR · 2025Review
- Tuberculosis Trends in the Post-COVID-19 Era: Is It Going to be a Global Concern?Health science reports · 2025Article
- Comprehensive review of preclinical evaluation strategies for COVID-19 vaccine candidates: assessing immunogenicity, toxicology, and safety profiles.Iranian journal of microbiology · 2025Review
- Rethinking Optimal Immunogens to Face SARS-CoV-2 Evolution Through Vaccination.Influenza and other respiratory viruses · 2025Review
- Fusion protein-based COVID-19 vaccines exemplified by a chimeric vaccine based on a single fusion protein (W-PreS-O).Frontiers in immunology · 2025Article
- Interaction between type 2 diabetes and past COVID-19 on active tuberculosis.BMC infectious diseases · 2024Article
- A review of the scientific literature on experimental toxicity studies of COVID-19 vaccines, with special attention to publications in toxicology journals.Archives of toxicology · 2024Review
- Omicron XBB.1.16-Adapted Vaccine for COVID-19: Interim Immunogenicity and Safety Clinical Trial Results.Vaccines · 2024Article
- The PHH-1V HIPRA vaccine: a new tool in the vaccination strategy against COVID-19.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Review
- Safety and immunogenicity of a recombinant protein RBD fusion heterodimer vaccine against SARS-CoV-2.NPJ vaccines · 2023Article
- Preclinical evaluation of PHH-1V vaccine candidate against SARS-CoV-2 in non-human primates.iScience · 2023Article
- Safety and immunogenicity of the protein-based PHH-1V compared to BNT162b2 as a heterologous SARS-CoV-2 booster vaccine in adults vaccinated against COVID-19: a multicentre, randomised, double-blind, non-inferiority phase IIb trial.The Lancet regional health. Europe · 2023Article
- Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.Frontiers in immunology · 2023Article
- Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19.Frontiers in bioengineering and biotechnology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
46 authors at 6 institutions in 1 country.
Antonio BarreiroHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Antoni PrenafetaHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Gregori Bech-SabatHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Mercè RocaHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Eva Perozo MurHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Ricard MarchHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Luis González-GonzálezHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Laia MadrenasHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Júlia CorominasHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Alex FernándezHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Alexandra MorosHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Manuel CañeteHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Mercè MolasHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Thais Pentinat-PelegrinHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Clara PanosaHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Alberto MorenoHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Ester Puigvert MolasHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Eva Pol VilarrassaHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Jordi PalmadaHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Carme GarrigaHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Teresa Prat CabañasHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Javier Iglesias-FernándezNostrum Biodiscovery, Avenue de Josep Tarradellas, 8-10, 3-2, 08029 Barcelona, Spain.
Júlia Vergara-AlertInstitut de Recerca i Tecnologia Agroalimentàries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, 08193 Cerdanyola del Vallès, Spain.
Cristina Lorca-OróInstitut de Recerca i Tecnologia Agroalimentàries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, 08193 Cerdanyola del Vallès, Spain.
Núria RocaInstitut de Recerca i Tecnologia Agroalimentàries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, 08193 Cerdanyola del Vallès, Spain.
Leira Fernández-BastitInstitut de Recerca i Tecnologia Agroalimentàries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, 08193 Cerdanyola del Vallès, Spain.
Jordi RodonInstitut de Recerca i Tecnologia Agroalimentàries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, 08193 Cerdanyola del Vallès, Spain.
Mònica PérezInstitut de Recerca i Tecnologia Agroalimentàries (IRTA), Centre de Recerca en Sanitat Animal (CReSA, IRTA-UAB), Campus de la UAB, 08193 Cerdanyola del Vallès, Spain.
Joaquim SegalésUniversitat Autònoma de Barcelona, CReSA (IRTA-UAB), Campus de la UAB, 08193 Cerdanyola del Vallès, Spain.
Edwards PradenasIrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain.
Silvia MarfilIrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain.
Benjamin TrinitéIrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain.
Raquel OrtizIrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain.
Bonaventura ClotetIrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain.
Julià BlancoIrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain.
Jorge Díaz PedrozaComparative Medicine and Bioimage Centre of Catalonia, Germans Trias i Pujol Research Institute (CMCiB-IGTP), 08916 Badalona, Spain.
Rosa Ampudia CarrascoComparative Medicine and Bioimage Centre of Catalonia, Germans Trias i Pujol Research Institute (CMCiB-IGTP), 08916 Badalona, Spain.
Yaiza Rosales SalgadoComparative Medicine and Bioimage Centre of Catalonia, Germans Trias i Pujol Research Institute (CMCiB-IGTP), 08916 Badalona, Spain.
Jordina Loubat-CasanovasComparative Medicine and Bioimage Centre of Catalonia, Germans Trias i Pujol Research Institute (CMCiB-IGTP), 08916 Badalona, Spain.
Sara Capdevila LarripaComparative Medicine and Bioimage Centre of Catalonia, Germans Trias i Pujol Research Institute (CMCiB-IGTP), 08916 Badalona, Spain.
Julia Garcia PradoIrsiCaixa. AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, UAB, 08916 Badalona, Spain.
Jordi BarretinaComparative Medicine and Bioimage Centre of Catalonia, Germans Trias i Pujol Research Institute (CMCiB-IGTP), 08916 Badalona, Spain.
Marta Sisteré-OróInfection Biology Laboratory, Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
Paula Cebollada RicaInfection Biology Laboratory, Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
Andreas MeyerhansInfection Biology Laboratory, Department of Experimental and Health Sciences (DCEXS), Universitat Pompeu Fabra (UPF), 08003 Barcelona, Spain.
Laura FerrerHIPRA, Avda. La Selva, 135, Amer, 17170 Girona, Spain.
Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol · ESCentre de Recerca en Sanitat Animal · ESIrsiCaixa · ESUniversitat Pompeu Fabra · ESUniversitat Autònoma de Barcelona · ESUniversitat de Vic - Universitat Central de Catalunya · ES
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current COVID-19 vaccines have been associated with a decline in infection rates, prevention of severe disease, and a decrease in mortality rates. However, SARS-CoV-2 variants are continuously evolving, and development of new accessible COVID-19 vaccines is essential to mitigate the pandemic. Here, we present data on preclinical studies in mice of a receptor-binding domain (RBD)-based recombinant protein vaccine (PHH-1V) consisting of an RBD fusion heterodimer comprising the B.1.351 and B.1.1.7 SARS-CoV-2 variants formulated in SQBA adjuvant, an oil-in-water emulsion. A prime-boost immunisation with PHH-1V in BALB/c and K18-hACE2 mice induced a CD4
Indexed as
Health sciencesImmune responseImmunologyMicrobiology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.